[{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","commit":"0bdbdae6c6","date":"2026-09-09","author":"Jude Gomila","message":"Editing pass: every TL;DR and summary stands alone","file":"src/data/gap-fill.ts","type":"changed","fields":[{"field":"tldr","before":"\"A Chinese PD-1 antibody approved in the US in 2025 for nasopharyngeal carcinoma, the second after toripalimab.\"","after":"\"Penpulimab is a Chinese PD-1 antibody approved in the US in 2025 for nasopharyngeal carcinoma, the second after toripalimab.\""}]},{"id":"penpulimab","kind":"drug","name":"Penpulimab","route":"/drugs/penpulimab/","commit":"71e4eef6e1","date":"2026-09-08","author":"Jude Gomila","message":"Gap audit and gap-fill data: 33 cancers, 87 products, 20 targets, 25 technologies, 12 terms, 18 collections","file":"src/data/gap-fill.ts","type":"added","fields":[{"field":"id"},{"field":"name"},{"field":"brand"},{"field":"modality"},{"field":"mechanism"},{"field":"status"},{"field":"wikipedia"},{"field":"tldr"},{"field":"summary"},{"field":"approvals"},{"field":"targets"},{"field":"cancers"},{"field":"companies"},{"field":"technologies"},{"field":"pathways"},{"field":"links"},{"field":"tags"}]}]